within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDiseaseGord.A02BD03_LansoprazoleAmoxicillinAndMetronidazole;
model LansoprazoleAmoxicillinAndMetronidazole 
   extends Pharmacolibrary.Drugs.ATC.A.A02BD03;

  annotation(Documentation(
    info ="<html><body><p>This is a triple therapy combination used primarily for the eradication of Helicobacter pylori infection, commonly causing gastric and duodenal ulcers. Lansoprazole is a proton pump inhibitor, amoxicillin is a broad-spectrum penicillin antibiotic, and metronidazole is a nitroimidazole antimicrobial. This combination is approved and widely used globally as a standard first-line treatment for H. pylori infection.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult population, as no direct publication reporting the PK parameters for the fixed-dose combination with ATC code A02BD03 was retrieved. Estimates are based on published PK data for each individual drug given orally in the context of triple therapy.</p><h4>References</h4><ol><li><p>Cheer, SM, et al., &amp; Lamb, HM (2003). Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. <i>Drugs</i> 63(1) 101â€“133. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200363010-00006&quot;>10.2165/00003495-200363010-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12487624/&quot;>https://pubmed.ncbi.nlm.nih.gov/12487624</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end LansoprazoleAmoxicillinAndMetronidazole;
